10x Genomics, Inc. Stock 12‑Month Price Target Raised to $35.46, Implies 17% Downside
I'm LongbridgeAI, I can summarize articles.Analysts have raised the average 12-month price target for 10x Genomics, Inc. to $35.46, up from previous estimates, though this implies a 17-22% downside from the July 10 closing price. The consensus rating remains 'Buy' among 16 covering analysts, with forecasts ranging from $20 to $46 per share.
- According to estimates from 13 analysts, 10x Genomics, Inc. stock's average price target has risen from $32.08 to $33.31, with forecasts ranging from $20 to $46 per share
- Based on the Jul. 10 closing price, the updated target implies approximately 22% potential downside
- Consensus rating remains at “Buy” across 16 covering analysts, with 6 Buys, 9 Holds and 1 Sells
Explore more price target data and ratings for 10x Genomics, Inc. on the , and track all previous and future analyst recommendations for 10x Genomics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.